Raymond James Financial Inc. Buys 28,430 Shares of Vaxcyte, Inc. $PCVX

Key Points

• Raymond James Financial Inc. has increased its stake in Vaxcyte, Inc. by 10.7%, now owning approximately 0.23% of the company's shares valued at $11.1 million.
• Wall Street analysts are optimistic about Vaxcyte, with a consensus Buy rating and an average target price of $136.50.
• Vaxcyte reported a loss of ($1.22) EPS for the last quarter, missing the consensus estimate of ($1.12) by ($0.10).

Raymond James Financial Inc. lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 10.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 293,134 shares of the company's stock after acquiring an additional 28,430 shares during the period. Raymond James Financial Inc. owned approximately 0.23% of Vaxcyte worth $11,069,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Rhumbline Advisers boosted its position in shares of Vaxcyte by 5.5% during the 1st quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock worth $6,843,000 after purchasing an additional 9,416 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Vaxcyte by 5.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company's stock worth $362,000 after buying an additional 524 shares during the period. Parallel Advisors LLC raised its holdings in Vaxcyte by 203.6% during the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after acquiring an additional 1,071 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of Vaxcyte by 75.4% during the first quarter. Envestnet Asset Management Inc. now owns 96,600 shares of the company's stock worth $3,648,000 after acquiring an additional 41,517 shares in the last quarter. Finally, Assetmark Inc. boosted its holdings in shares of Vaxcyte by 1,758.8% in the first quarter. Assetmark Inc. now owns 14,424 shares of the company's stock worth $545,000 after acquiring an additional 13,648 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Wall Street Analyst Weigh In

Separately, Cowen reissued a "buy" rating on shares of Vaxcyte in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Price Performance

NASDAQ PCVX traded up $0.77 on Tuesday, reaching $31.56. 1,852,955 shares of the company's stock traded hands, compared to its average volume of 1,470,702. The stock has a market cap of $4.10 billion, a PE ratio of -7.68 and a beta of 1.04. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06. The stock has a 50-day simple moving average of $33.24 and a 200 day simple moving average of $41.73.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter in the prior year, the firm earned ($1.10) EPS. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.